First ‘histology-independent’ treatment for solid tumours with a specific gene mutation

July 26, 2019 – EMA’s human medicines committee (CHMP) has recommended granting a marketing authorisation in the European Union for larotrectinib for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. Treatment with larotrectinib is recommended for patients whose disease has spread or cannot be surgically removed, and who have no other satisfactory treatment options. Larotrectinib … (leggi tutto)